nsclc - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

AstraZeneca’s Tagrisso divides on immediate adoption in adjuvant non-small cell lung cancer

Tagrisso’s improved efficacy and safety profile in general versus the older EGFR TKIs and the DFS data was adequate to make treatment choices. Credit: Shutterstock.